Key result
The intrinsic ligand of zELK potassium channels acts as an allosteric modulator that dynamically rearranges during voltage-dependent potentiation, switching from an antagonist to an agonist.
The intrinsic ligand of KCNH potassium channels dynamically regulates channel gating by switching from an antagonist to an agonist during voltage-dependent potentiation.
Extends KCNH channel insights from animal models; leaves open translation to human cardiac electrophysiology.
KCNH voltage-gated potassium channels (EAG, ERG, and ELK) play significant roles in neuronal and cardiac excitability. They contain cyclic nucleotide-binding homology domains (CNBHDs) but are not directly regulated by cyclic nucleotides. Instead, the CNBHD ligand-binding cavity is occupied by an intrinsic ligand, which resides at the intersubunit interface between the N-terminal eag domain and the C-terminal CNBHD. We show that, in Danio rerio ELK channels, this intrinsic ligand is critical for voltage-dependent potentiation (VDP), a process in which channel opening is stabilized by prior depolarization. We demonstrate that an exogenous peptide corresponding to the intrinsic ligand can bind to and regulate zebrafish ELK channels. This exogenous intrinsic ligand inhibits the channels before VDP and potentiates the channels after VDP. Furthermore, using transition metal ion fluorescence resonance energy transfer and a fluorescent noncanonical amino acid L-Anap, we show that there is a rearrangement of the intrinsic ligand relative to the CNBHD during VDP. We propose that the intrinsic ligand switches from antagonist to agonist as a result of a rearrangement of the eag domain–CNBHD interaction during VDP.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2018) studied this question. Intrinsic-ligand peptide vs. Control was evaluated on Voltage-dependent potentiation (VDP). The intrinsic ligand of zELK potassium channels acts as an allosteric modulator that dynamically rearranges during voltage-dependent potentiation, switching from an antagonist to an agonist.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: